Trump Administration Proposes MFN Deals in Pharmacy Sector
A new proposal from the Trump administration is urging Congress to solidify agreements with manufacturers partaking in Most Favored Nation (MFN) arrangements with the government. This initiative, spotlighted by President Trump in his February 24, 2026, State of the Union address, remains a focal topic among administration officials.
Recent disclosures in Securities and Exchange Commission filings reveal insights from several companies engaged in MFN agreements. Sixteen companies are sharing various deal specifics, reflecting heightened transparency in the pharmaceutical sector amid regulatory compliance requirements.
The Centers for Medicare & Medicaid Services (CMS) has extended the application deadline for the voluntary Generous payment model for Medicaid to April 30, 2026. This move was indicated on the CMS Generous website and is mirrored in their official Request for Applications.
The Medicare payment model discussions persist post-comment period closure on February 23, 2026, as policymakers deliberate over feedback. Democratic Congressional members are actively seeking further clarity on these impactful MFN agreements.
Pharmacy and Regulatory Concerns
Criticism is emanating from the pharmacy sector concerning Maximum Fair Prices (MFPs), particularly those influenced by the Inflation Reduction Act, effective January 1, 2026. These regulatory developments heighten scrutiny on their impact on the pricing landscape.
Pharmaceutical manufacturers are increasingly demanding claims-level data from covered entities on 340B program dispensations, adhering to stringent data requirements. Initially imposed by a major manufacturer, this protocol has now been broadly adopted.
Litigation and Legislative Actions
The Health Resources & Services Administration (HRSA) has addressed feedback on its 340B Rebate Model Pilot Program by extending the commentary period to April 20, 2026. Additionally, legal challenges against HRSA's registration waivers, originally instituted during the COVID-19 pandemic, are currently ongoing in the US District Court for the District of Columbia.
HRSA has also updated its Administrative Dispute Resolution (ADR) website with a new decision summary, marking the fifth update under the revised ADR process. State legislative measures prohibiting drug manufacturers from restricting contract pharmacy access are gaining traction, with several states also mandating 340B discount disclosures.
Continuing legal battles, including those confronting the Oregon Prescription Drug Price Transparency Program, highlight pharmaceutical manufacturers' ongoing resistance to state-level regulatory interventions. These developments underscore the evolving nature of regulatory compliance in the pharmaceutical and broader insurance sectors.